Affinage

NPY1R

Neuropeptide Y receptor type 1 · UniProt P25929

Length
384 aa
Mass
44.4 kDa
Annotated
2026-06-10
35 papers in source corpus 21 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NPY1R (Y1 receptor) is a neuropeptide Y/peptide YY receptor that acts as a cell-autonomous brake on cAMP signaling and, through this and downstream cascades, governs metabolism, nociception, neuroplasticity, and stress physiology (PMID:41412283). In adipocytes NPY signaling through NPY1R dose-dependently attenuates lipolysis and cAMP signaling, with receptor abundance tracking adiposity such that reduced NPY1R licenses beta-adrenergic lipolysis (PMID:41412283); an analogous cAMP/PKA/CREB-restraining role operates in intestinal epithelium, where NPY1R induction limits NF-κB-driven IL-6/NLRP3 inflammation and supports barrier integrity (PMID:41657307). In the spinal dorsal horn, NPY1R-expressing interneurons partition into Grp/Npy1r, Npff/Npy1r, and Cck/Npy1r subsets, with the Grp/Npy1r population specifically required for NPY-mediated analgesia in neuropathic pain (PMID:37824208); a subset of these neurons co-express the μ-opioid receptor, and NPY acting through NPY1R synergistically enhances morphine analgesia (PMID:41738433). In limbic and cortical circuits, NPY1R enhances GABAergic inhibitory tone in the medial prefrontal cortex (PMID:32492699), positions upstream of serotonergic tone in the orbitofrontal cortex to support behavioral flexibility (PMID:29353053), and regulates HPA axis activity, anxiety, and body weight in a sex-dependent manner (PMID:32755609); in the hippocampus it forms heteroreceptor complexes with GALR2 and TrkB linked to neuroblast proliferation and memory (PMID:38425430, PMID:38667284, PMID:38622072, PMID:38572811). NPY1R transcription is epigenetically silenced by promoter methylation driven by UHRF1 (PMID:41657307) and by lncRNA MCM3AP-AS1-mediated DNMT recruitment (PMID:32193153). The NPY/NPY1R axis drives cancer phenotypes, promoting pancreatic cancer liver metastasis (PMID:40073121) and marking an LGR5+ colorectal stem cell population that serves as a cancer cell of origin (PMID:40897804).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2003 High

    Established whether NPY1R is singularly required for NPY's orexigenic effect, revealing functional redundancy with the Y5 receptor.

    Evidence Chronic ICV NPY infusion in Npy1r and Npy5r knockout mice with feeding, adiposity, and hypothalamic mRNA readouts

    PMID:14525913

    Open questions at the time
    • Does not resolve receptor-specific contributions when both are functional
    • No cell-type or circuit resolution of the redundancy
  2. 2018 High

    Placed NPY1R upstream of serotonergic tone in cortical circuits controlling behavioral flexibility, linking the receptor to executive function rather than only feeding.

    Evidence Conditional Npy1r KO in Y5R neurons; reversal learning, OFC c-Fos and 5-HT fiber immunohistochemistry, SSRI rescue

    PMID:29353053

    Open questions at the time
    • Mechanism connecting NPY1R signaling to serotonergic fiber density unknown
    • Receptor-intrinsic signaling step not defined
  3. 2020 High

    Defined NPY1R's circuit-level action in limbic/cortical neurons, showing it enhances GABAergic inhibition and controls HPA/anxiety/metabolic outputs sex-dependently.

    Evidence Maternal separation and conditional KO mice; mPFC electrophysiology with receptor blockade, RNAseq, neuroendocrine and adiposity measurements

    PMID:32492699 PMID:32755609

    Open questions at the time
    • Molecular basis of estrogen-dependent sex divergence not resolved
    • Direct receptor signaling to GABAergic transmission not reconstituted
  4. 2020 Medium

    Identified epigenetic silencing of NPY1R by lncRNA-directed DNMT recruitment as a driver of prostate cancer, framing NPY1R as a methylation-controlled tumor suppressor in this context.

    Evidence RIP, RNA pull-down, ChIP, methylation-specific PCR, NPY1R overexpression rescue, and xenografts in prostate cancer cells

    PMID:32193153

    Open questions at the time
    • How NPY1R loss feeds MAPK activation mechanistically unclear
    • Single tumor-type model
  5. 2022 Medium

    Showed NPY1R mediates NPY's growth-inhibitory effect on estrogen-driven breast cancer, extending its tumor-modulating role to hormone-responsive cancers.

    Evidence NPY treatment with NPY1R antagonist BIBP-3226 in ER+ breast cancer cells and xenografts

    PMID:35121782

    Open questions at the time
    • Downstream signaling linking NPY1R to growth inhibition undefined
    • Single antagonist used
  6. 2023 High

    Resolved NPY1R spinal interneurons into molecular subtypes and pinpointed the Grp/Npy1r population as necessary for NPY analgesia, giving cell-type precision to the receptor's antinociceptive role.

    Evidence Cross-species FISH, chemogenetic inhibition, subtype-specific conditional Npy1r deletion, intrathecal Y1 agonist in neuropathic pain models

    PMID:37824208

    Open questions at the time
    • Circuit output of Grp/Npy1r neurons not fully mapped
    • Signaling within these interneurons not characterized
  7. 2024 Medium

    Demonstrated NPY1R participates in heteroreceptor complexes with GALR2 and TrkB supporting hippocampal neurogenesis and memory, but follow-up knockdown showed plasticity is preserved via compensation, qualifying the functional weight of these complexes.

    Evidence In situ proximity ligation assay, ICV/intranasal drug administration, neurogenesis markers and memory tasks; ICV siRNA knockdown with PLA and behavioral readouts

    PMID:38425430 PMID:38572811 PMID:38622072 PMID:38667284 PMID:41307298

    Open questions at the time
    • Complexes shown only by PLA, not co-IP or reconstitution
    • Compensatory mechanisms preserving plasticity unidentified
  8. 2025 High

    Established the cell-autonomous, cAMP-restraining mechanism of NPY1R in human adipocytes and intestinal epithelium, unifying its metabolic and anti-inflammatory actions through cAMP/PKA/CREB suppression.

    Evidence Primary human adipocyte lipolysis and cAMP assays with snRNAseq and clinical meta-analysis; intestinal epithelial UHRF1 KO mouse with cAMP/PKA/CREB and NF-κB signaling readouts

    PMID:41412283 PMID:41657307

    Open questions at the time
    • Coupling to specific Gi/o subtypes not detailed in corpus
    • Tissue-specific effector divergence not fully mapped
  9. 2025 High

    Showed UHRF1-mediated promoter methylation as a second epigenetic axis controlling NPY1R, controlling intestinal inflammation and barrier function.

    Evidence Intestinal epithelial-specific UHRF1 KO mouse, ChIP, methylation analysis, downstream signaling and barrier assays

    PMID:41657307

    Open questions at the time
    • Stimuli regulating UHRF1 recruitment to NPY1R unknown
    • Relationship to the lncRNA-DNMT axis not integrated
  10. 2025 High

    Defined the NPY/NPY1R axis as pro-metastatic in pancreatic cancer and identified NPY1R+ cells as a colorectal cancer cell of origin, casting NPY1R as a context-dependent oncogenic driver distinct from its tumor-suppressive role elsewhere.

    Evidence Autochthonous and intrasplenic pancreatic metastasis models with genetic KO and BIBO3304; CreERT2 lineage tracing of NPY1R+ LGR5+ colon stem cells with Wnt/Kras/Trp53 manipulation

    PMID:40073121 PMID:40897804

    Open questions at the time
    • Signaling driving migration and stemness downstream of NPY1R not resolved
    • Basis for opposing oncogenic vs suppressive roles across tissues unexplained
  11. 2025 High

    Linked NPY1R to the μ-opioid system, showing NPY1R+ spinal neurons require MOR for morphine analgesia and that NPY synergizes with morphine via NPY1R.

    Evidence In situ hybridization, conditional Oprm1 KO in NPY1R+ neurons, chemogenetics, intrathecal NPY with antagonist, Npy1r-/- mice, and spinal slice electrophysiology

    PMID:41738433

    Open questions at the time
    • Molecular cross-talk between NPY1R and MOR signaling not defined
    • Convergent intracellular pathway not identified
  12. 2025 Medium

    Extended NPY1R signaling to additional peripheral effector pathways (CREB/NLRP3-driven senescence, vascular phenotypic switching via tyrosine phosphorylation, osteogenic PI3K/AKT/mTOR), broadening its mechanistic repertoire beyond cAMP inhibition.

    Evidence In vivo agonist/antagonist in ovarian granulosa cells; Co-IP of TK-NPY1R with TKI rescue in aneurysm model; iPSC osteogenesis with PAM inhibition

    PMID:39353356 PMID:41268237 PMID:42262763

    Open questions at the time
    • Identity of the tyrosine kinase phosphorylating NPY1R not established
    • Osteogenic link to PI3K lacks direct binding/signaling evidence
    • Tissue-specific effector switching mechanism unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single Gi-coupled, cAMP-inhibiting receptor produces tumor-suppressive effects in some cancers but pro-metastatic and stem-cell-origin effects in others, and how its signaling diverges across tissues, remains unresolved.
  • No unifying account of context-dependent NPY1R output
  • Receptor-proximal effector selection across tissues uncharacterized
  • Structural basis of ligand/effector coupling not addressed in corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0098772 molecular function regulator activity 2
Localization
GO:0005886 plasma membrane 2
Pathway
R-HSA-112316 Neuronal System 3 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 2 R-HSA-1430728 Metabolism 1
Partners
GALR2OPRM1TRKB

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Genetic redundancy between NPY1R (Y1) and NPY5R (Y5) receptor signaling in NPY-mediated control of food intake: mice lacking either Npy1r or Npy5r still showed full feeding and obesity responses to chronic intracerebroventricular NPY infusion, indicating that neither receptor alone is solely required when the other is present. Chronic ICV NPY infusion in Npy1r and Npy5r knockout mice; measurement of food intake, fat pad weight, plasma insulin/leptin/corticosterone, and hypothalamic NPY/POMC mRNA Endocrinology High 14525913
2018 Conditional inactivation of Npy1r in Y5R-containing neurons (Npy1rY5R-/- mice) impairs behavioral flexibility (reversal learning) and causes decreased serotonergic fiber density and increased baseline neural activity (c-Fos) in the orbitofrontal cortex; acute escitalopram treatment restores OFC activity and behavioral flexibility, placing Y1R upstream of serotonergic tone in OFC circuits. Conditional KO mouse model (Npy1rY5R-/- mice); Morris water maze and water T-maze reversal learning; immunohistochemical quantification of c-Fos and 5-HT fibers in OFC; pharmacological rescue with SSRI escitalopram Neuropharmacology High 29353053
2020 NPY1R signaling in the medial prefrontal cortex enhances GABAergic inhibitory currents: maternally deprived mice show upregulated Npy1r expression and increased inhibitory synaptic inputs to mPFC neurons, and pharmacological blockade of NPY1R reduces GABAergic currents specifically in these animals. Maternal separation protocol in mice; RNAseq for gene expression changes; electrophysiological recordings (mPFC) with NPY1R pharmacological blockade; dendritic morphology analysis Neuropsychopharmacology High 32492699
2020 Conditional inactivation of Npy1r in limbic excitatory neurons produces sex-specific metabolic and behavioral phenotypes: male Npy1rrfb mice show HPA hyperactivation, anxiety, reduced body weight and adiposity; female Npy1rrfb mice show anxiety but no HPA or body weight changes, instead accumulating more WAT with compensatory reduction of AgRP in the arcuate nucleus, indicating estrogen-dependent relay that maintains homeostasis. Conditional KO mice (Npy1rrfb); behavioral tests; HPA axis hormone measurements; fat pad weighing; plasma leptin; AgRP immunoreactivity in arcuate nucleus; Npy1r mRNA quantification by brain region and sex Hormones and behavior High 32755609
2020 The lncRNA MCM3AP-AS1 recruits DNMT1/DNMT3A/DNMT3B to the NPY1R promoter, promoting its methylation and transcriptional silencing, thereby activating the MAPK pathway to drive prostate cancer cell proliferation, invasion, and migration; NPY1R overexpression reverses MCM3AP-AS1-driven tumor growth in vivo. RNA immunoprecipitation, RNA pull-down, chromatin immunoprecipitation (ChIP), methylation-specific PCR; NPY1R overexpression rescue; xenograft tumor model; scratch/Transwell/EdU/flow cytometry assays Molecular therapy. Nucleic acids Medium 32193153
2022 NPY1R mediates inhibitory effects of NPY on estradiol-stimulated growth of ER+ breast cancer cells: NPY treatment reduces estradiol-stimulated cell growth, and this effect is reversed by the NPY1R antagonist BIBP-3226. NPY treatment with/without NPY1R antagonist BIBP-3226 in ER+ BC cell lines; cell growth assays; xenograft models; endocrine therapy resistance cell models in vitro and in vivo Scientific reports Medium 35121782
2023 Within the spinal dorsal horn, NPY1R interneurons (Y1-INs) segregate into three largely non-overlapping subpopulations (Grp/Npy1r, Npff/Npy1r, Cck/Npy1r); specifically, Grp/Npy1r interneurons are necessary for NPY-mediated analgesia in neuropathic pain — intrathecal Y1 agonist reduces neuropathic hypersensitivity in mice lacking Npy1r in CCK- and NPFF-INs but not in GRP-INs. Fluorescence in situ hybridization (FISH) to characterize Y1-IN subpopulations in mice, non-human primates, and humans; chemogenetic inhibition of Npff/Npy1r-INs; conditional deletion of Npy1r from CCK-INs and NPFF-INs; intrathecal Y1 agonist [Leu31,Pro34]-NPY; neuropathic pain behavioral assays JCI insight High 37824208
2024 NPY1R forms heteroreceptor complexes with GALR2 and with TrkB in the dentate gyrus of the hippocampus; co-activation of NPY1R and GALR2 increases co-localization signals and neuroblast proliferation, and co-administration of NPY1R agonist with ketamine increases NPY1R-TrkB complex formation and BDNF expression, associated with enhanced neurogenesis and memory consolidation. In situ proximity ligation assay (PLA) for receptor co-localization; intracerebroventricular or intranasal drug administration; PCNA and DCX immunohistochemistry for neurogenesis; object-in-place memory task Frontiers in cellular neuroscience / Cells / Expert opinion on therapeutic targets Medium 38425430 38572811 38622072 38667284
2024 NPY1R-TrkB and NPY1R-GALR2 heteroreceptor complexes in the ventral hippocampus are disrupted by ICV siRNA knockdown of NPY1R; this disruption does not alter hippocampal neurogenesis (PCNA counts), BDNF expression, or depressive-like behavior (forced swim test), indicating compensatory mechanisms that preserve plasticity despite receptor complex loss. ICV Accell siRNA knockdown of NPY1R; in situ PLA for NPY1R-GALR2 and NPY1R-TrkB complexes; PCNA immunolabeling; BDNF immunostaining; forced swim test Journal of psychopharmacology Medium 41307298
2025 NPY1R exerts a cell-autonomous brake on adipocyte lipolysis: NPY dose-dependently attenuates lipolysis and cAMP signaling in primary human subcutaneous adipocytes; NPY1R expression correlates positively with adiposity and decreases after weight loss, with reduced NPY1R associated with enhanced beta-adrenergic-induced lipolysis. Single nuclei RNA sequencing of scWAT before/after lifestyle intervention; pharmacological NPY treatment in primary human adipocytes; cAMP signaling assays; meta-analysis of 23 clinical studies Molecular metabolism High 41412283
2025 NPY/NPY1R signaling promotes pancreatic cancer metastasis to the liver: pancreas-specific and whole-body Npy1r knockout, as well as pharmacological inhibition with BIBO3304, significantly reduces liver metastasis in autochthonous KPR172HC mouse models and in an intrasplenic metastasis model; BIBO3304 reduces cancer cell migration on cell-derived matrices. Genetically engineered autochthonous KPR172HC mouse model with pancreas-specific and whole-body Npy1r KO; intrasplenic metastasis model; NPY1R antagonist BIBO3304 treatment; cell migration assays on cell-derived matrices Science advances High 40073121
2025 NPY1R identifies a colon-specific LGR5+ stem cell population in the middle and distal colorectum; selective dysregulation of Wnt signaling in NPY1R+ stem cells using CreERT2 lines drives colon cancer initiation predominantly in the rectum, establishing NPY1R+ stem cells as a source of colorectal cancer. CreERT2 mouse lines targeting NPY1R+ cells; conditional Wnt signaling activation; combination with oncogenic Kras and Trp53 loss; histological and cancer progression analysis Nature cell biology High 40897804
2025 UHRF1 binds the NPY1R promoter, promotes its methylation, and suppresses NPY1R transcription in intestinal epithelial cells; UHRF1 deficiency upregulates NPY1R, which attenuates cAMP/PKA/CREB signaling, enhances NF-κB activation and proinflammatory IL-6/NLRP3 expression, and compromises intestinal epithelial barrier integrity. UHRF1 KO mouse model (intestinal epithelial-specific); human cell models; ChIP for UHRF1 binding to NPY1R promoter; methylation analysis; cAMP/PKA/CREB and NF-κB signaling assays; ELISA for IL-6; barrier integrity assays JCI insight High 41657307
2025 MOR (μ-opioid receptor, Oprm1) is co-expressed in ~21% of NPY1R+ interneurons in the spinal dorsal horn; MOR activation in NPY1R+ interneurons is required for morphine analgesia — conditional deletion of Oprm1 from NPY1R+ neurons impairs morphine analgesia. Intrathecal NPY synergistically enhances morphine analgesia via NPY1R, an effect abolished by NPY1R antagonism or Npy1r knockout. NPY1R+ neuron hyperexcitability induced by inflammation is suppressed by morphine. In situ hybridization; conditional Oprm1 KO in NPY1R+ neurons (AAV-Npy1r-Cre-EGFP); chemogenetic approaches; intrathecal NPY +/- NPY1R antagonist; Npy1r-/- mice; whole-cell electrophysiology of spinal cord slices; multiple pain models Brain : a journal of neurology High 41738433
2025 NPY1R is phosphorylated by tyrosine kinase (TK), and TK inhibition (TKI) suppresses NPY1R-mediated promotion of vascular smooth muscle cell phenotypic transition (contractile-to-synthetic), inflammatory response, and M1 macrophage polarization in an intracranial aneurysm mouse model; macrophage ablation abolished NPY1R overexpression-mediated promotion of aneurysm formation. Co-immunoprecipitation (Co-IP) validating TK-NPY1R interaction; NPY1R overexpression in IA mouse model; TKI treatment; flow cytometry for immune cell populations; ELISA for inflammatory factors; HE staining Neuropeptides Medium 39353356
2025 NPY1R activates PI3K/AKT/mTOR (PAM) signaling to support osteogenic differentiation: NPY1R suppression reduced osteogenic capacity of iPSCs, and PAM pathway inhibition with LY294002 decreased osteogenic activity; NPY1R and PAM pathway activation were confirmed in vivo in a rat periodontitis model during bone repair. Transcriptomic profiling of iPSC osteogenic differentiation; NPY1R knockdown; LY294002 PAM pathway inhibition; in vivo rat periodontitis model with NPY1R and pathway marker analysis American journal of translational research Low 41268237
2025 NPY1R overexpression in ovarian granulosa cells activates p-CREB signaling, promotes IL-6 and NLRP3 expression, induces ROS accumulation, ferroptosis, and mitochondrial dysfunction, accelerating ovarian senescence; NPY1R antagonist BIBO 3304 reverses these phenotypes in vivo. In vivo NPY1R agonist ([Leu31,Pro34]-NPY) and antagonist (BIBO 3304) administration in mice; transcriptome sequencing of aged human granulosa cells; ROS and mitochondrial assays; estrous cycle monitoring; follicular development analysis; CREB, IL-6, NLRP3 measurement FASEB journal Medium 42262763
2025 Nobiletin (NOB) directly binds NPY1R (confirmed by molecular docking) and reduces Npy1r overexpression in pancreatic β-cells; NOB mitigates NPY1R-mediated β-cell insulin secretion deficiency by activating the RORs/Bmal1-YAP clock-modulatory pathway, suppressing YAP and activating Bmal1, thereby restoring insulin secretion in T2DM mouse models. Molecular docking for NOB-NPY1R interaction; Bmal1::Luc bioluminescence rhythmicity in MIN6 cells; NPY1R antagonist (BMS 193885) and palmitic acid/NPY interventions; T2DM mouse models (HFD+STZ and acute NPY hyperglycemia); Npy1r expression analysis in β-cells Molecular nutrition & food research Medium 40913544
2025 In the gut, PYY-expressing colonic L-cells release PYY which acts on NPY1R-expressing enterochromaffin (EC) cells to enhance serotonin release and gut pain sensitivity in a female-specific estrogen-responsive paracrine circuit. Preprint: identification of NPY1R expression on EC cells; estrogen receptor alpha signaling manipulation; PYY/NPY1R pharmacological dissection in colonic circuit; gut pain behavioral assays bioRxivpreprint Low

Source papers

Stage 0 corpus · 35 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R. BMC medical genetics 64 15090072
2003 Chronic neuropeptide Y infusion into the lateral ventricle induces sustained feeding and obesity in mice lacking either Npy1r or Npy5r expression. Endocrinology 38 14525913
2020 MCM3AP-AS1 KD Inhibits Proliferation, Invasion, and Migration of PCa Cells via DNMT1/DNMT3 (A/B) Methylation-Mediated Upregulation of NPY1R. Molecular therapy. Nucleic acids 24 32193153
2022 NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Scientific reports 22 35121782
2020 Social subordination induced by early life adversity rewires inhibitory control of the prefrontal cortex via enhanced Npy1r signaling. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 16 32492699
2023 Alleviation of neuropathic pain with neuropeptide Y requires spinal Npy1r interneurons that coexpress Grp. JCI insight 15 37824208
2020 Conditional inactivation of Npy1r gene in mice induces sex-related differences of metabolic and behavioral functions. Hormones and behavior 12 32755609
2020 Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction. Biochimica et biophysica acta. General subjects 11 32007578
2022 Integrative Analysis of Exosomal miR-452 and miR-4713 Downregulating NPY1R for the Prevention of Childhood Obesity. Disease markers 10 35401881
2018 Conditional inactivation of Npy1r gene in mice induces behavioural inflexibility and orbitofrontal cortex hyperactivity that are reversed by escitalopram. Neuropharmacology 10 29353053
2024 Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions. Behavioral and brain functions : BBF 7 38549164
2025 Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Science advances 6 40073121
2024 Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition. Frontiers in cellular neuroscience 6 38425430
2024 Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 6 38572811
2024 Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats. Cells 6 38667284
2024 Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder. Expert opinion on therapeutic targets 5 38622072
2024 Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus. Expert opinion on therapeutic targets 5 38626283
2021 Theoretical study of the interactions between peptide tyrosine tyrosine [PYY (1-36)], a newly identified modulator in type 2 diabetes pathophysiology, with receptors NPY1R and NPY4R. Hormones (Athens, Greece) 5 33782920
2009 Three common variants of LEP, NPY1R and GPR54 show no association with age at menarche. Hormone research 5 19506390
2025 NOX1 and NPY1R mark regional colon stem cell populations that serve as cancer origins in vivo. Nature cell biology 4 40897804
2025 Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: Novel biomarkers for early Alzheimer's disease detection. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 1 40618588
2025 Skin Resident T Cell Interactions with NPY1R+ Neurons During Wound Repair Are Impaired by Obesity. bioRxiv : the preprint server for biology 1 40661589
2025 Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour. Journal of psychopharmacology (Oxford, England) 1 41307298
2023 Design of Novel Imidazopyrazine Derivative against Breast Cancer via Targeted NPY1R Antagonist. Anti-cancer agents in medicinal chemistry 1 37151057
2026 Sex-related differences in aggressive and emotional behavior in mice with the conditional inactivation of limbic Npy1r. Hormones and behavior 0 41579511
2026 68Ga/211At-Labeled Specific NPY1R Peptide-Based Molecular Probe for Glioma-Targeted Imaging and Alpha Therapy. Biomacromolecules 0 41607110
2026 UHRF1 deficiency exacerbates intestinal inflammation by epigenetic modulation of NPY1R gene methylation. JCI insight 0 41657307
2026 Distinct contribution of spinal neuropeptide Y and NPY1R neurons to morphine analgesia. Brain : a journal of neurology 0 41738433
2026 Effects of Npy1r limbic conditional knock-out on adipose tissue metabolism. Neuropharmacology 0 41866109
2026 Mechanism and Intervention of the NPY1R/CREB Signaling Axis in Regulating Inflammatory Response in Aged Ovarian Granulosa Cells and Ovarian Senescence. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 42262763
2025 LncRNA RWDD3 Facilitates Leydig Cell Steroidogenesis by Regulating the miR-1388-5p/NPY1R/cAMP Pathway in Yanshan Cashmere Goats. Animals : an open access journal from MDPI 0 40646785
2025 Nobiletin Alleviates Npy1r-Mediated Insulin Secretion Deficiency of Islet β-Cells via the Clock-Modulatory Signaling. Molecular nutrition & food research 0 40913544
2025 Transcriptome analysis of induced pluripotent stem cells' osteogenic differentiation reveals NPY1R activating PI3K/AKT/mTOR in alveolar bone loss during periodontitis. American journal of translational research 0 41268237
2025 Single cell transcriptomics of human weight loss links adipocyte NPY1R to control of lipolysis. Molecular metabolism 0 41412283
2024 Phosphorylated NPY1R regulates phenotypic transition of vascular smooth muscle cells, inflammatory response and macrophage infiltration to promote intracranial aneurysm progression. Neuropeptides 0 39353356

Missed literature

Know a paper Affinage missed for NPY1R? Flag it for the maintainers and the community.

No submissions yet.